Literature DB >> 17267332

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

Carlos Frangié1, Carmen Lefaucheur, Jacques Medioni, Christian Jacquot, Garry S Hill, Dominique Nochy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17267332     DOI： 10.1016/S1470-2045(07)70037-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  42 in total

Review 1.  Bevacizumab increases risk for severe proteinuria in cancer patients.

Authors:  Shenhong Wu; Christi Kim; Lea Baer; Xiaolei Zhu
Journal:  J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 10.121

Review 2.  The risk for anemia with targeted therapies for solid tumors.

Authors:  Sandro Barni; Mary Cabiddu; Paolo Guarneri; Veronica Lonati; Fausto Petrelli
Journal:  Oncologist       Date:  2012-04-24

3.  TGF-β-activated kinase 1 is crucial in podocyte differentiation and glomerular capillary formation.

Authors:  Sung Il Kim; So-Young Lee; Zhibo Wang; Yan Ding; Nadeem Haque; Jiwang Zhang; Jing Zhou; Mary E Choi
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

Review 4.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 5.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

6.  A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors:  R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal:  Gynecol Oncol       Date:  2013-01-13       Impact factor: 5.482

7.  Turning a blind eye to anti-VEGF toxicities.

Authors:  Susan E Quaggin
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 8.  Proteinuria in preeclampsia from a podocyte injury perspective.

Authors:  Daniel E Henao; Moin A Saleem
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

9.  A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Authors:  Brian I Rini; Jorge A Garcia; Matthew M Cooney; Paul Elson; Allison Tyler; Kristi Beatty; Joseph Bokar; Tarek Mekhail; R M Bukowski; G Thomas Budd; Pierre Triozzi; Ernest Borden; Percy Ivy; Helen X Chen; Afshin Dolwati; Robert Dreicer
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

10.  Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.